Synapse Open Synapse
Biology

Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

BioPharma Dive · · 2 min read

The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.

Latest from BioPharma Dive